Keywords
Cisplatin
Non-small cell lung cancer
Clinical value
Submitted : 2023-05-27
Accepted : 2023-06-11
Published : 2023-06-26
Abstract
Objective: To analyze the clinical value of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer (NSCLC). Methods: Sixty-nine patients in Shengli Oilfield Central Hospital were recruited between May 2021 and August 2022 and separated into the observation group (n = 35) and the control group (n = 34). Cisplatin combined with pemetrexed (the observation group) and cisplatin combined with gemcitabine (the control group) were used for treatment, respectively, and the therapeutic effects of the two groups were compared. Results: There was no significant difference in the disease control rate between the two groups (P > 0.05); the immune function indexes of the patients in the observation group were significantly higher than those in the control group after treatment (P < 0.05); there was no significant difference in the incidence of nausea and vomiting as well as hair loss (P > 0.05), but the incidence of blood toxicity in the observation group was significantly lower than that in the control group (P < 0.05). Conclusion: Pemetrexed plus cisplatin in NSCLC patients has an ideal effect, and it can improve the quality of life of patients and reduce adverse reactions, which has clinical promotion value.
References
Li Y, Liu J, Zhou Z, et al., 2018, Comparative Study of Pemetrexed and Gemcitabine Combined with Cisplatin in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer. J Bengbu Med Coll, 43(6): 719–722.
Xue Y, Jia J, Wu Y, et al., 2018, Clinical Effects of Gemcitabine and Pemetrexed Combined with Cisplatin in the Treatment of Non-Small Cell Lung Cancer. PLA J Med, 30(12): 11–14.
Chen C, Wang Y, Zhou Y, 2018, Clinical Feasibility of Pemetrexed Combined with Cisplatin in the Treatment of Non-Small Cell Lung Cancer. J Pract Cancer, 33(6): 941–943.
Zhu Y, Wang R, Li A, et al., The Effect of Pemetrexed Combined with Cisplatin on the Expression of CEA and Other Markers in Patients with Advanced Non-Small Cell Lung Cancer. J Diff Dis, 20(10): 982–986.
Huang H, Chen T, 2018, The Effect of Pemetrexed Combined with Cisplatin on Serum Tumor Markers in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. Drug Eval Res, 41(12): 2289–2293.
Meng J, Wang M, Li J, et al., 2018, Clinical Study of Crizotinib versus Pemetrexed Disodium Combined with Cisplatin in the First-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer. Int Oncol J, 45(1): 63–64.
Wang Y, Quan L, 2020, Effects of Pemetrexed and Cisplatin Combined with Gefitinib on T Cell Subsets and Cytokines in Patients with Lung Cancer. Southeast Def Med, 22(1): 43–47.
Luo X, Ma Y, Sun Z, et al., 2019, Clinical Research on Xiaoai Ping Tablets Combined with PC Regimen in the Treatment of Advanced Non-Small Cell Lung Cancer. Mod Drugs Clinics, 34(2): 424–428.
Li Z, Yang Y, Zhang L, 2018, Application of Gemcitabine or Pemetrexed Intravenous Chemotherapy Combined with Cisplatin Pleural Infusion in Non-Small Cell Lung Cancer with Malignant Pleural Effusion. Cancer Prog, 16(3): 342–344 + 374.
Jia L, Zhu Y, Fu Y, et al., 2018, Efficacy and Safety Evaluation of Compound Matrine Injection on Pemetrexed Combined with Carboplatin Regimen in the Treatment of Non-Small Cell Lung Cancer. Chin Mod Appl Pharm, 35(10): 1533–1537.
Wang W, Dong L, Li H, et al., 2020, Clinical Observation of Anlotinib Combined with Chemotherapy as Second-Line Treatment of Advanced Non-Small Cell Lung Cancer with Acquired Resistance to Tyrosine Kinase Inhibitors. Chin J Cancer Prevent Treat, 27(20): 1669–1673.
Gao N, Wang C, 2022, Clinical Efficacy Study of Thymosin Combined with Cisplatin and Pemetrexed Disodium in the Treatment of Advanced Non-Small Cell Lung Cancer. Shaanxi Med J, 51(11): 1424–1427.
Li Z, Yang D, He W, et al., 2022, Application Effect of Brucea javanica Oil Emulsion Injection Combined with Pemetrexed + Cisplatin Chemotherapy in Non-Small Cell Lung Cancer. Cancer Prog, 20(7): 672–675.
Chang Y, Zhang L, Wang H, et al., 2022, Observation on the Curative Effect of Gefitinib Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer. Chin Cancer Clinic Rehab, 29(2): 129–133.
Zhang Y, Mo Q, He X, et al., 2018, Clinical Efficacy of Pemetrexed Combined with Cisplatin in the Treatment of Non-Small Cell Lung Cancer and Its Impact on the Quality of Life of Patients. Cancer Prog, 16(13): 1601–1603.
Qiu P, Zhang Q, Chen L, et al., 2020, Efficacy of Pemetrexed Combined with Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer and Its Impact on Patients’ Toxic and Side Effects and 1-Year Survival Rate. Hebei Med, 26(3): 506–510.